Article with Dr. Joanna Fowler

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood. TriRima is a member of a new class of selective and reversible inhibitors of MAO-A known as RIMAs, and it is the first whose mechanism has been validated in human brain imaging studies.

Read More: Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A

 

Annual Meeting

Program CoverThe ACNP Annual Meeting is one of the world's leading forums for the exchange of cutting edge scientific information about the brain, behavior, and psychotropic drugs.

ACNP Publications

Program CoverThe College offers a variety of Publications with the latest and most comprehensive research in psychopharmacology and related fields.

Research Discussions

This forum enables discussion of articles that have appeared in Neuropsychopharmacology. It is intended to stimulate scholarly interactions among researchers, and to help educate members of the public who are interested in psychiatric illness.